Patient-reported disease burden in the Accelerate Clinical Trials in Charcot-Marie-Tooth Disease Study.
CMT
CMT HI
CMT Health Index
CMT1A
Charcot–Marie–tooth disease
MCID
clinical trial design
patient‐reported outcomes
quality of life
sex differences
Journal
Journal of the peripheral nervous system : JPNS
ISSN: 1529-8027
Titre abrégé: J Peripher Nerv Syst
Pays: United States
ID NLM: 9704532
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
revised:
20
09
2024
received:
23
06
2024
accepted:
23
09
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
11
10
2024
Statut:
aheadofprint
Résumé
The Charcot-Marie-Tooth Disease Health Index (CMT-HI) is a disease-specific, patient-reported disease burden measure. As part of an international clinical trial readiness study, individuals with CMT1A (ages 18-75 years) underwent clinical outcome assessments (COAs), including the CMT-HI, to capture their longitudinal perspective on the disease burden. Two hundred and fifteen participants underwent serial COAs including the CMT-HI, CMT Functional Outcome Measure (CMT-FOM), CMT Neuropathy Score (CMTNSv2R), and CMT Exam Score (CMTES/CMTES-R). Correlations between the total and subscale scores for the CMT-HI and other COAs were determined. Changes in the CMT-HI scores over 12 months were assessed using paired t-tests. The minimum clinically important difference (MCID) for the CMT-HI and its subscales were calculated by anchoring to a participant global impression of change scale. At baseline, CMT1A participants were 44.5 ± 15 years old (range: 18-75) and 58% were women. The mean CMT-HI was 25.7 ± 18.8 (range: 0-91.9; 100 reflecting maximal disease burden). The CMT-HI correlated with the CMT-FOM (r = .54, p < .0001), CMTNSv2R (r = .48, p < .0001), and CMTES/CMTES-R (r = .52/r = .54, p < .0001). Disease burden was greater in women than in men (CMT-HI 29.1 ± 19.1 vs. 21.2 ± 17.3, p = .001). Over 12 months, there was a nonsignificant mean increase in CMT-HI of 0.40 ± 10.0 (n = 189, p = .89). The MCID for the CMT-HI total score was 3.8 points (95% CI: 1.7-5.9). Patient-reported disease burden in CMT1A as measured by the CMT-HI is associated with measures of neurologic impairment and physical functioning. Women reported a higher disease burden than men. These data will inform the design of clinical trials in CMT1A.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The Charcot-Marie-Tooth Disease Health Index (CMT-HI) is a disease-specific, patient-reported disease burden measure. As part of an international clinical trial readiness study, individuals with CMT1A (ages 18-75 years) underwent clinical outcome assessments (COAs), including the CMT-HI, to capture their longitudinal perspective on the disease burden.
METHODS
METHODS
Two hundred and fifteen participants underwent serial COAs including the CMT-HI, CMT Functional Outcome Measure (CMT-FOM), CMT Neuropathy Score (CMTNSv2R), and CMT Exam Score (CMTES/CMTES-R). Correlations between the total and subscale scores for the CMT-HI and other COAs were determined. Changes in the CMT-HI scores over 12 months were assessed using paired t-tests. The minimum clinically important difference (MCID) for the CMT-HI and its subscales were calculated by anchoring to a participant global impression of change scale.
RESULTS
RESULTS
At baseline, CMT1A participants were 44.5 ± 15 years old (range: 18-75) and 58% were women. The mean CMT-HI was 25.7 ± 18.8 (range: 0-91.9; 100 reflecting maximal disease burden). The CMT-HI correlated with the CMT-FOM (r = .54, p < .0001), CMTNSv2R (r = .48, p < .0001), and CMTES/CMTES-R (r = .52/r = .54, p < .0001). Disease burden was greater in women than in men (CMT-HI 29.1 ± 19.1 vs. 21.2 ± 17.3, p = .001). Over 12 months, there was a nonsignificant mean increase in CMT-HI of 0.40 ± 10.0 (n = 189, p = .89). The MCID for the CMT-HI total score was 3.8 points (95% CI: 1.7-5.9).
DISCUSSION
CONCLUSIONS
Patient-reported disease burden in CMT1A as measured by the CMT-HI is associated with measures of neurologic impairment and physical functioning. Women reported a higher disease burden than men. These data will inform the design of clinical trials in CMT1A.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : #NIH 1U01 NS109403
Pays : United States
Investigateurs
Peter Creigh
(P)
Nicole Koopman
(N)
Elizabeth Wood
(E)
Gabrielle Donlevy
(G)
Kayla Cornett
(K)
Paula Bray
(P)
Melissa Mandarakas
(M)
Chiara Pisciotta
(C)
Eleonora Cavalca
(E)
Giulia Schirinzi
(G)
Paola Saveri
(P)
Luca Crivellari
(L)
Matilde Laura
(M)
Luke O Donnell
(LO)
Menelaos Pipis
(M)
Mariola Skorupinska
(M)
Gita Ramadharry
(G)
Amy DMcDowell
(A)
John Thornton
(J)
Jasper Morrow
(J)
Thomas Woodford
(T)
Informations de copyright
© 2024 Peripheral Nerve Society.
Références
Morena J, Gupta A, Hoyle JC. Charcot‐Marie‐Tooth: from molecules to therapy. Int J Mol Sci. 2019;20(14):3419. doi:10.3390/ijms20143419
Johnson NE, Heatwole CR, Ferguson M, Sowden JE, Jeanat S, Herrmann DN. Patient identification of the symptomatic impact of charcot‐marie‐tooth disease type 1A. J Clin Neuromuscul Dis. 2013;15(1):19‐23. doi:10.1097/CND.0b013e31829e22e3
Karadima G, Floroskufi P, Koutsis G, Vassilopoulos D, Panas M. Mutational analysis of PMP22, GJB1 and MPZ in Greek Charcot–Marie–Tooth type 1 neuropathy patients. Clin Genet. 2011;80(5):497‐499. doi:10.1111/j.1399‐0004.2011.01657.x
Braathen GJ. Genetic epidemiology of Charcot‐Marie‐Tooth disease. Acta Neurol Scand Suppl. 2012;193:iv‐22. doi:10.1111/ane.12013
Theadom A, Roxburgh R, MacAulay E, et al. Prevalence of Charcot‐Marie‐Tooth disease across the lifespan: a population‐based epidemiological study. BMJ Open. 2019;9(6):e029240. doi:10.1136/bmjopen‐2019‐029240
Wise CA, Garcia CA, Davis SN, et al. Molecular analyses of unrelated Charcot‐Marie‐Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplication. Am J Hum Genet. 1993;53(4):853‐863.
Fridman V, Sillau S, Acsadi G, et al. A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology. 2020;94:e884‐e896. doi:10.1212/WNL.0000000000009035
Rehbein T, Wu TT, Treidler S, et al. Neuropathy due to bi‐allelic SH3TC2 variants: genotype‐phenotype correlation and natural history. Brain. 2023;146(9):3826‐3835. doi:10.1093/brain/awad095
Pipis M, Feely SME, Polke JM, et al. Natural history of Charcot‐Marie‐Tooth disease type 2A: a large international multicentre study. Brain. 2020;143:3589‐3602. doi:10.1093/brain/awaa323
Food and Drug Administration. Guidance for Industry: Patient‐Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009.
Johnson NE, Heatwole C, Creigh P, et al. The Charcot‐Marie‐Tooth health index: evaluation of a patient‐reported outcome. Ann Neurol. 2018;84(2):225‐233. doi:10.1002/ana.25282
Eichinger K, Sowden JE, Burns J, et al. Accelerate clinical trials in Charcot‐Marie‐Tooth disease (ACT‐CMT): a protocol to address clinical trial readiness in CMT1A. Front Neurol. 2022;13:930435. doi:10.3389/fneur.2022.930435
Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology. 2005;64:1209‐1214. doi:10.1212/01.WNL.0000156517.00615.A3
Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot‐Marie‐Tooth disease. J Peripher Nerv Syst. 2011;16:191‐198. doi:10.1111/j.1529‐8027.2011.00350.x
Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry. 2006;77(8):973‐976. doi:10.1136/jnnp.2005.081547
Eichinger K, Burns J, Cornett K, et al. The Charcot‐Marie‐Tooth functional outcome measure (CMT‐FOM). Neurology. 2018;91(15):e1381‐e1384. doi:10.1212/WNL.0000000000006323
Mandarakas MR, Eichinger KJ, Bray P, et al. Multicenter validation of the Charcot‐Marie‐Tooth functional outcome measure. Neurology. 2024;102(3):e207963. doi:10.1212/WNL.0000000000207963
Pisciotta C, Ciafaloni E, Zuccarino R, et al. Charcot‐Marie‐Tooth Health Index (CMT‐HI): validation of the Italian version. J Peripher Nerv Syst. 2020;25(4):470.
Colomban C, Micallef J, Lefebvre MN, et al. Clinical spectrum and gender differences in a large cohort of Charcot‐Marie‐Tooth type 1A patients. J Neurol Sci. 2014;336(1‐2):155‐160. doi:10.1016/j.jns.2013.10.029
Pisciotta C, Calabrese D, Santoro L, et al. Pregnancy in Charcot‐Marie‐Tooth disease: data from the Italian CMT national registry. Neurology. 2020;95(24):e3180‐e3189. doi:10.1212/WNL.0000000000010860
Swan ER, Fuerst DR, Shy ME. Women and men are equally disabled by Charcot‐Marie‐Tooth disease type 1A. Neurology. 2007;68(11):873. doi:10.1212/01.wnl.0000256818.43819.da
Pareyson D, Dell'Anna E, DiMonda T, et al. Influence of gender and pregnancy on CMT1A. J Peripher Nerv Syst. 2004;9(2):118. doi:10.1111/j.1085‐9489.2004.009209at.x
Melcangi RC, Cavarretta IT, Ballabio M, et al. Peripheral nerves: a target for the action of neuroactive steroids. Brain Res Brain Res Rev. 2005;48(2):328‐338. doi:10.1016/j.brainresrev.2004.12.021